US Stock MarketDetailed Quotes

ELTX Elicio Therapeutics

Watchlist
  • 8.170
  • +0.480+6.24%
Close Feb 14 16:00 ET
98.47MMarket Cap-1.88P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jan 22 06:31
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
    Wednesday, 22nd January at 7:30 am
    Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
    Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival ("DFS") expected in H1 2025; positive results could support rapid advan...
    Trytosaveabit
    Trytosaveabit
    Dec 12, 2024 06:13
    Update
    $Elicio Therapeutics (ELTX.US)$ Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    GlobeNewswire· 12 mins ago
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
    Jaguar8
    Jaguar8
    Dec 12, 2024 06:04
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    Thursday, 12th December at 7:00 am
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 20...
    Jaguar8
    Jaguar8
    Dec 3, 2024 06:05
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
    Tuesday, 3rd December at 7:00 am
    BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the completion of enrollment in the Phase 2 AMPLIFY-7P study (NCT05726864). The randomized Phase 2 st...
    Jaguar8
    Jaguar8
    Nov 7, 2024 15:06
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
    Elicio Therapeutics presented updated preliminary results from the AMPLIFY-7P Phase 1 clinical trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. Key findings show mKRAS-specific T cell responses in all evaluable patients, with the 4.9 mg dose group showing 12-fold higher ...
Read more

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
PILOT
831175
+30.00%
XINGANJIANG
873167
+29.99%
Beijing Highlander Digital Technology
300065
+20.05%
4
Hangzhou Gaoxin Materials Technology
300478
+20.02%
5
Shijihengtong Technology
301428
+20.01%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Earnings Season Underway
Earnings season is here. What to know?
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!